Hair Loss Treatment Categories Compared

How to read this comparison

Hair loss is not one condition, and no single treatment category fits every type. Alopecia is the broad term for hair loss from part of the head or body, and it includes common patterns such as androgenetic alopecia (male- and female-pattern hair loss), alopecia areata, and telogen effluvium. Because the underlying process differs, the treatment categories that make sense differ too.

This page compares treatment categories rather than brands or clinics. The useful comparison is not which product is best; it is what each category does, how it is typically used, how long it may take to show an effect, and what evidence still leaves uncertain. That framing is designed to support an informed conversation with a clinician, not to replace one.

Topical treatments applied to the scalp
Oral medications taken by mouth
Procedural and in-office options
Observational and supportive approaches
The limits of the evidence and open questions

Sources: Wikipedia, Suncoast Skin Solutions (commercial dermatology clinic), Lasers in Medical Science (PMC), Cleveland Clinic

Topical treatment categories

Topical treatments are applied directly to the scalp. Two categories dominate the discussion: topical minoxidil, which is available over the counter for pattern hair loss in both men and women, and topical corticosteroids, which are used for inflammatory hair loss such as alopecia areata. They are not interchangeable; they target different processes.

Topical minoxidil is described as prolonging the growth phase of the hair cycle rather than curing the underlying cause of hair loss. Clinicians typically expect that it must be continued to maintain any benefit. Topical corticosteroids, by contrast, are used to calm immune activity in alopecia areata, and reviews indicate they should be assessed over months rather than days. Real-world U.S. claims data show corticosteroids as the most common first-line and second-line treatment for alopecia areata, though that describes prescribing patterns, not proof of superiority over other options.

Topical minoxidil: over-the-counter for pattern hair loss; effect depends on continued use
Topical corticosteroids: prescription anti-inflammatory approach for alopecia areata
Route matters: topical application suits limited or accessible areas of the scalp
Assessment over months is typical before judging whether a topical approach is working

Sources: U.S. Pharmacist (Jobson Medical Information), Suncoast Skin Solutions (commercial dermatology clinic), Wikipedia, International Journal of Trichology (PMC), Acta Dermato-Venereologica (PMC), Osmosis from Elsevier

Oral treatment categories

Oral treatment categories fall into three broad groups in the sources reviewed here: 5-alpha-reductase inhibitors for pattern hair loss, oral corticosteroids and other immunosuppressants for alopecia areata, and FDA-approved Janus kinase (JAK) inhibitors for severe alopecia areata.

Finasteride is described as a 5-alpha-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone. In the U.S. it is used off-label for androgenetic alopecia in men, and the topical formulation is not available in the United States. Dutasteride is FDA-approved for benign prostatic hyperplasia; its use for androgenetic alopecia in the U.S. is off-label. For alopecia areata, oral corticosteroids and other immunosuppressants appear in the evidence as options that clinicians may consider in severe or refractory cases rather than routine first-line therapy.

For severe alopecia areata, the FDA-approved oral JAK inhibitors described in the sources are baricitinib (Olumiant, authorized June 2022), ritlecitinib (Litfulo, approved June 2023), and deuruxolitinib (Leqselvi, approved July 2024). Deuruxolitinib 8 mg tablets is labeled for adults with severe alopecia areata and carries boxed warnings including serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis; it is also contraindicated in CYP2C9 poor metabolizers and with moderate or strong CYP2C9 inhibitors.

5-alpha-reductase inhibitors: oral finasteride for pattern hair loss in men (off-label in the U.S.); dutasteride off-label for this use
Corticosteroids and other immunosuppressants: sometimes considered for severe or refractory alopecia areata
JAK inhibitors: FDA-approved for severe alopecia areata in adults, with boxed warnings and contraindications
Oral routes are systemic, so the risk profile differs from topical application

Sources: U.S. Pharmacist (Jobson Medical Information), Lasers in Medical Science (PMC), Yahoo Finance (syndicated), International Journal of Trichology (PMC), GoodRx, Wikipedia, Sun Pharmaceutical Industries Limited via PR Newswire, BioSpace

Procedural and in-office options

Procedural options include intralesional corticosteroid injections and hair transplantation. They are in-office procedures rather than home treatments, and each addresses a different problem.

Intralesional corticosteroid injections deliver medication directly into affected areas and are used for patchy alopecia areata. The supplied reviews describe triamcinolone acetonide at 5 to 10 mg/mL injected every four to six weeks. One review notes that intralesional steroid injections are not recommended for rapidly progressing alopecia areata, alopecia totalis, or alopecia universalis, which is a genuine boundary rather than a minor caveat.

Hair transplantation relocates hair follicles from an androgen-resistant donor area, typically the back or sides of the scalp, into androgen-dependent areas. The two commonly described surgical techniques are follicular unit transplantation (FUT) and follicular unit extraction (FUE). Results are described as typically lasting over 20 years, but non-transplanted hair can continue to thin, so density may decrease over time. A review also notes that ongoing pharmacologic therapy is often part of the plan. Candidacy is assessed by a clinician based on the type and stability of the hair loss and the availability of donor hair.

Intralesional corticosteroid injections: direct injection for patchy alopecia areata, commonly every 4 to 6 weeks
Not typically used for rapidly progressing, totalis or universalis forms
Hair transplant: moving follicles from resistant donor areas to thinning areas
FUT (strip) and FUE (extraction) are the two commonly described techniques
Transplant does not stop the underlying pattern; ongoing medical therapy is often discussed

Sources: International Journal of Trichology (PMC), Canadian Family Physician (PMC), Osmosis from Elsevier, Dr.Oracle (clinical reference aggregator), U.S. Pharmacist (Jobson Medical Information), Lasers in Medical Science (PMC), Suncoast Skin Solutions (commercial dermatology clinic)

Observational and supportive approaches

Some approaches are described as supportive rather than disease-modifying. Low-level laser therapy (LLLT), sometimes called photobiomodulation, is used for androgenetic alopecia through devices such as combs, caps or helmets. Device clearance and drug approval are different regulatory paths, and this category does not carry the same evidence weight as the medications described above.

Supplements and stress-reduction measures also appear in consumer-facing material. Stress reduction may help diffuse alopecia areata in some descriptions, but supplements are not regulated by the FDA in the same way as prescription drugs, and the evidence reviewed here does not support treating them as equivalent to approved therapies. Observation is itself a legitimate approach for some presentations, particularly where hair loss is mild, self-limited, or where treatment would not change the underlying course.

Low-level laser therapy / photobiomodulation: device-based category for pattern hair loss
Supplements: not regulated by the FDA like prescription drugs; evidence for hair regrowth is not established here
Stress reduction: described as supportive for some diffuse presentations
Observation: a reasonable category when hair loss is mild or expected to be self-limited

Sources: U.S. Pharmacist (Jobson Medical Information), Social Health Network, Healthline, Canadian Family Physician (PMC), Cleveland Clinic

Evidence limitations and what is not known

The evidence base for hair loss treatment is uneven. Several of the sources reviewed here state plainly that treatment for alopecia areata does not appear to change the ultimate natural course of the disease, even when it helps regrow hair in the short term. There is no established cure for alopecia areata or androgenetic alopecia in these sources, and severe subtypes such as alopecia totalis and alopecia universalis are described as less likely to respond.

Several practical questions are not settled. The optimal duration, intensity, and device selection for low-level laser therapy remain unclear in the material reviewed. Quantitative figures for laser therapy come from a secondary summary rather than a primary meta-analysis, so they should be treated cautiously. Comparisons between named products or branded devices are not well supported by the evidence reviewed here; the honest unit of comparison is the treatment category.

The sources reviewed also do not establish verified U.S. prices, insurance coverage determinations, prior-authorization rules, or state-level restrictions for these treatments. These vary by provider, plan and location, and should be confirmed directly rather than assumed.

Treatment may help regrowth without altering the long-term course of alopecia areata
Severe subtypes are generally less responsive
Optimal low-level laser therapy parameters are not well established
Category-level comparisons are better supported than branded, head-to-head comparisons
Cost, coverage and access vary and are not fixed facts that apply uniformly

Sources: International Journal of Trichology (PMC), Canadian Family Physician (PMC), Wikipedia, Cleveland Clinic, Dr.Oracle (clinical reference aggregator), U.S. Pharmacist (Jobson Medical Information), Acta Dermato-Venereologica (PMC)

What minoxidil is and how it is thought to work

Minoxidil is a topical medication used for pattern hair loss. Its mechanism is described as prolonging the growth phase of the hair cycle rather than reversing the underlying cause of hair loss.

A practical point emphasized in the sources is timing. Visible response usually takes about 12 weeks before hair begins to grow, and the medication must be continued to maintain any effect; hair growth subsides if it is stopped. That expectation-setting matters, because a person who stops at four weeks may conclude the treatment failed when it simply has not had time to work.

Over-the-counter topical medication for pattern hair loss in men and women
Thought to work by prolonging the growth phase of the hair cycle
Typically about 12 weeks before hair begins to grow
Continued use is required to maintain effect

Sources: U.S. Pharmacist (Jobson Medical Information), Suncoast Skin Solutions (commercial dermatology clinic), Wikipedia, Cleveland Clinic

What finasteride is and its approved use context in the U.S.

Finasteride is an oral 5-alpha-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone. It is used for androgenetic alopecia in men; in the U.S., the topical formulation is not available.

The term approved use context matters here. Finasteride has FDA approval as a medication for androgenetic alopecia, but the evidence reviewed for this page does not include an FDA drug label document, so the exact approved indication wording cannot be verified from these sources. It is described as contraindicated in women of childbearing age. Dutasteride is a related oral medication; it is FDA-approved for benign prostatic hyperplasia, and its use for androgenetic alopecia in the U.S. is off-label.

Oral 5-alpha-reductase inhibitor used for androgenetic alopecia in men
Topical finasteride is not available in the United States
Contraindicated in women of childbearing age
Dutasteride: FDA-approved for benign prostatic hyperplasia; off-label for androgenetic alopecia in the U.S.
Exact FDA-approved indication wording should be confirmed with a clinician or the current label

Sources: U.S. Pharmacist (Jobson Medical Information), Lasers in Medical Science (PMC), Yahoo Finance (syndicated)

What corticosteroids are and which alopecia types they are considered for

Corticosteroids are anti-inflammatory medications that can be applied topically, injected into the scalp, or taken orally. They are considered mainly for alopecia areata, an immune-mediated condition in which the immune system attacks hair follicles. They are not a standard treatment category for pattern hair loss.

The route chosen depends on the extent and location of hair loss. For mild or patchy alopecia areata, topical corticosteroids are often described as first-line, and intralesional injections of triamcinolone acetonide are used directly into affected areas, commonly every four to six weeks. Reviews note that intralesional injections are not recommended for rapidly progressing alopecia areata, alopecia totalis, or alopecia universalis. Topical corticosteroids are generally used for at least three months before regrowth is expected, and they are typically stopped at six months if there is no new hair growth.

Route options: topical application, intralesional injection, or oral dosing
Mainly considered for alopecia areata, not pattern hair loss
Topical corticosteroids: often first-line for mild or patchy disease
Intralesional triamcinolone acetonide: 5 to 10 mg/mL, commonly every 4 to 6 weeks
Not typically recommended for rapidly progressing, totalis or universalis forms
Assessment period for topical use is measured in months, not days

Sources: Cleveland Clinic, IMARC Group, International Journal of Trichology (PMC), Canadian Family Physician (PMC), Osmosis from Elsevier, Dr.Oracle (clinical reference aggregator)

What a hair transplant is and how candidacy is assessed

A hair transplant moves hair follicles from an androgen-resistant donor area, usually the back or sides of the scalp, into areas where hair has thinned. Because the transplanted follicles come from a region not typically affected by pattern hair loss, they tend to persist. The two commonly described techniques are FUT (follicular unit transplantation) and FUE (follicular unit extraction).

Candidacy is assessed on several factors. The type of hair loss matters, since transplantation is used for androgenetic alopecia rather than inflammatory conditions such as alopecia areata. Stability of the pattern matters, because ongoing loss can change the appearance of the result. Donor hair availability sets the practical ceiling on how much can be transplanted, and the presence of continued loss in non-transplanted hair means density may decrease over time.

In the sources reviewed, results are described as typically lasting over 20 years, with the important caveat that non-transplanted hair can continue to thin. That is why ongoing medical therapy is frequently discussed alongside transplantation. The evidence reviewed here does not include U.S. professional-society guidance on surgeon credentialing or graft-survival benchmarks.

Relocates follicles from androgen-resistant donor areas to thinning areas
Two commonly described techniques: FUT and FUE
Used for androgenetic alopecia, not for alopecia areata
Candidacy turns on hair-loss type, pattern stability, and available donor hair
Results are described as typically lasting over 20 years, with continued thinning of non-transplanted hair
Ongoing medical therapy is often part of the overall plan

Sources: U.S. Pharmacist (Jobson Medical Information), Lasers in Medical Science (PMC), Suncoast Skin Solutions (commercial dermatology clinic)

What low-level laser therapy and photobiomodulation refer to

Low-level laser therapy (LLLT), also referred to as photobiomodulation, is a device-based category used for androgenetic alopecia. Devices take forms such as combs, caps or helmets, and they are regulated through device clearance rather than drug approval.

The evidence picture here is thinner than for the medication categories. In the material reviewed, one summary reported that a meta-analysis found a mean difference in hair count of about 17.7 hairs per square centimeter versus placebo, and that at the time of publication only one laser comb had FDA clearance. That same summary noted more information is needed on optimal use. No primary meta-analysis or systematic review of LLLT appears in the sources reviewed here, so these figures should be treated as a secondary summary rather than a definitive quantitative benchmark.

Device-based category for pattern hair loss; not a drug approval
Devices include combs, caps and helmets
Secondary summary reports a mean hair-count difference versus placebo, with more information needed on optimal use
No primary systematic review of LLLT was available in the sources reviewed

Sources: U.S. Pharmacist (Jobson Medical Information)

Factors clinicians consider when choosing an approach

The choice among treatment categories is not a single decision. It depends on the type of alopecia, the extent and location of hair loss, the age of the person, and the risks and monitoring each option requires. Two people with similar-looking thinning can have different diagnoses and therefore different appropriate categories.

Several factors recur across the sources. The diagnosis comes first, because corticosteroids are considered for alopecia areata while minoxidil and finasteride are used for pattern hair loss. Extent matters because intralesional injections are not recommended for totalis or universalis presentations. Age matters in practice; a U.S. claims analysis found adolescents with alopecia areata were less likely than adults to receive injectable corticosteroids and more likely to receive topical corticosteroids, which the authors attribute in part to injection discomfort.

Timeline expectations also shape the conversation. Topical corticosteroids are generally assessed over at least three months, minoxidil over roughly twelve weeks, and transplantation over months as well. Treatment for alopecia areata is aimed at halting disease activity and promoting regrowth, not at guaranteeing a cure.

Diagnosis first: pattern hair loss and alopecia areata use different categories
Extent and location of hair loss
Age and tolerability, including discomfort from injections
Timeline expectations for each category
Whether treatment is intended to change the course of disease or manage appearance
Monitoring requirements and individual risk factors

Sources: International Journal of Trichology (PMC), Canadian Family Physician (PMC), Acta Dermato-Venereologica (PMC), Cleveland Clinic, Osmosis from Elsevier, U.S. Pharmacist (Jobson Medical Information)

Side-by-side category and decision-criteria matrix

The table below compares treatment categories on the attributes that the sources reviewed actually support: the type of alopecia each category is considered for, how it is used, the typical assessment timeline where stated, and the most important limitation. It is a category-level comparison, not a ranking, and it does not compare named products or devices.

The decision criteria that follow the table are derived from the same sources rather than from any single published decision tree. They are organized to help a visitor prepare for a clinical conversation, not to substitute for clinical judgment.

Decision criterion 1: What is the diagnosis? Pattern hair loss and alopecia areata use different treatment categories.
Decision criterion 2: How extensive is the hair loss? Some categories are not recommended for totalis or universalis presentations.
Decision criterion 3: How much time is acceptable before judging results? Timelines differ by category.
Decision criterion 4: What monitoring or risk management does each option require?
Decision criterion 5: Is the goal regrowth, slowing progression, or appearance change?
Decision criterion 6: What does the person prefer in terms of route, setting and frequency?

Category-level comparison of hair loss treatment approaches
Treatment category	Main alopecia type considered	Route or setting	Typical assessment timeline	Key limitation
Topical minoxidil	Pattern hair loss (androgenetic)	Home, topical	About 12 weeks before hair begins to grow	Must be continued to maintain effect
Oral finasteride	Pattern hair loss (androgenetic)	Home, oral	Not stated consistently in the sources reviewed	Used for men; contraindicated in women of childbearing age
Corticosteroids (topical, intralesional, oral)	Alopecia areata	Home topical, in-office injection, or oral	At least 3 months for topical; injections commonly every 4 to 6 weeks	Intralesional injections not recommended for rapidly progressing, totalis or universalis forms
Oral JAK inhibitors	Severe alopecia areata	Home, oral	Trial endpoints in manufacturer reporting used a 24-week primary endpoint	Boxed warnings and contraindications; cost and monitoring requirements
Hair transplant	Pattern hair loss (androgenetic)	In-office surgical	Results generally evident over months	Non-transplanted hair can continue to thin; candidacy depends on donor hair
Low-level laser therapy / photobiomodulation	Pattern hair loss (androgenetic)	Home, device	Not well established in the sources reviewed	Optimal use is not well established; evidence is thinner than for medications

Sources: U.S. Pharmacist (Jobson Medical Information), Suncoast Skin Solutions (commercial dermatology clinic), Wikipedia, Lasers in Medical Science (PMC), International Journal of Trichology (PMC), Canadian Family Physician (PMC), Osmosis from Elsevier, Dr.Oracle (clinical reference aggregator), Cleveland Clinic, Acta Dermato-Venereologica (PMC), GoodRx, Sun Pharmaceutical Industries Limited via PR Newswire, BioSpace

Questions to ask a qualified clinician before starting a treatment

Preparing questions in advance makes a clinical visit more productive. The list below is organized around the decisions that treatment categories actually require, and it applies whether the conversation is about a topical, oral, procedural or observational approach.

Because treatment aims and evidence limits differ by category, answers may vary. The goal of asking is not to find a single right answer but to understand why a particular category is being recommended for a particular diagnosis and situation.

What type of alopecia do I have, and how was that determined?
What is the goal of the treatment you are recommending: regrowth, slowing progression, or appearance change?
How long should I expect before judging whether it is working, and what counts as a response?
What are the known risks, warnings and contraindications for this option in my situation?
What happens if I stop the treatment?
Are there options we are not considering, and why?
What monitoring or follow-up will this require?
How does my age, sex and other health conditions affect the choice?

Sources: International Journal of Trichology (PMC), Canadian Family Physician (PMC), Cleveland Clinic, Osmosis from Elsevier, U.S. Pharmacist (Jobson Medical Information), Sun Pharmaceutical Industries Limited via PR Newswire, BioSpace, Acta Dermato-Venereologica (PMC)

Frequently asked questions

Which hair loss treatment works best?

There is no single best category because hair loss is not one condition. Topical and oral medications are used for pattern hair loss, corticosteroids and JAK inhibitors are used for alopecia areata, and transplantation is used for pattern hair loss in selected candidates. The appropriate category depends on the diagnosis, the extent of hair loss, and individual factors. Even within a category, the sources reviewed note that treatment for alopecia areata does not appear to change the ultimate natural course of the disease, so "best" needs to be defined in terms of a specific goal.

Sources: International Journal of Trichology (PMC), Canadian Family Physician (PMC), Lasers in Medical Science (PMC), Cleveland Clinic

Are over-the-counter treatments effective for pattern hair loss?

Topical minoxidil is the main over-the-counter medication described for pattern hair loss in men and women. It is thought to work by prolonging the growth phase of the hair cycle, and it typically takes about 12 weeks before hair begins to grow. It must be continued to maintain effect. Over-the-counter status does not mean it works for every type of hair loss; it is described for pattern hair loss, not for inflammatory conditions such as alopecia areata.

Sources: U.S. Pharmacist (Jobson Medical Information), Suncoast Skin Solutions (commercial dermatology clinic), Cleveland Clinic, Wikipedia

How long before a treatment shows results?

Timelines differ by category. Topical minoxidil usually takes about 12 weeks before hair begins to grow. Topical corticosteroids are generally used for at least three months before regrowth is expected and are typically stopped at six months if there is no new hair growth. Intralesional corticosteroid injections are commonly given every four to six weeks. For hair transplantation, results are generally evident over months. These are typical assessment windows, not guarantees for an individual.

Sources: Cleveland Clinic, International Journal of Trichology (PMC), Osmosis from Elsevier, Dr.Oracle (clinical reference aggregator), U.S. Pharmacist (Jobson Medical Information)

Can treatments be combined?

Combination use appears in the sources: a first-line regimen for alopecia areata has been described as intralesional triamcinolone together with topical steroids, minoxidil, or both. In pattern hair loss, ongoing pharmacologic therapy is often discussed alongside transplantation because non-transplanted hair can continue to thin. Whether combining categories is appropriate depends on the diagnosis, the specific options, and individual risk factors, so it is a decision to make with a clinician rather than by adding products independently.

Sources: Canadian Family Physician (PMC), U.S. Pharmacist (Jobson Medical Information), Lasers in Medical Science (PMC)

Is minoxidil a cure for hair loss?

No. Minoxidil is described as prolonging the growth phase of the hair cycle rather than curing the underlying cause of hair loss. The sources reviewed do not establish a cure for androgenetic alopecia or alopecia areata. Minoxidil can support regrowth or maintenance while it is used, but continued use is required to maintain the effect.

Sources: Suncoast Skin Solutions (commercial dermatology clinic), U.S. Pharmacist (Jobson Medical Information), Cleveland Clinic

What happens if I stop using minoxidil?

The sources describe minoxidil as requiring continued use, with the effect subsiding if it is stopped. In practical terms, any benefit gained during use would be expected to be lost over time after discontinuation. The sources reviewed do not provide a precise washout timeline for how quickly that occurs.

Sources: U.S. Pharmacist (Jobson Medical Information), Suncoast Skin Solutions (commercial dermatology clinic)

Is finasteride safe for women?

Finasteride is described as contraindicated in women of childbearing age, and its use for androgenetic alopecia is described in the context of men. The sources reviewed here do not support a general statement that finasteride is safe or appropriate for women. Whether any form of anti-androgen therapy might be considered for a specific woman is a clinical decision based on her situation and should be discussed with a qualified clinician.

Sources: Lasers in Medical Science (PMC), U.S. Pharmacist (Jobson Medical Information)

Do laser caps really work for hair loss?

Low-level laser therapy, including caps, combs and helmets, is a device-based category used for pattern hair loss. One summary in the sources reviewed reported a meta-analysis finding a mean difference in hair count of about 17.7 hairs per square centimeter versus placebo, but the same summary noted that more information is needed on optimal use, and no primary systematic review of this therapy appears in the sources reviewed here. Device clearance is also a different regulatory path from drug approval. The honest answer is that this category has some reported signal but less certainty than the medication categories.